Description: Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Home Page: www.takeda.com
1-1, Nihonbashi-Honcho 2-chome
Tokyo,
103-8668
Japan
Phone:
81 3 3278 2111
Officers
| Name | Title |
|---|---|
| Mr. Christophe Weber | Pres, CEO & Representative Director |
| Mr. Constantine Saroukos | CFO & Representative Director |
| Dr. Andrew S. Plump | Pres of R&D and Representative Director |
| Dr. Seigo Izumo | Chair of Management Board |
| Mr. Haruhiko Hirate | Member of Management Board |
| Salvatore Alesci | Member of Management Board and Head of R&D Global Science & Biomedical Policy |
| Norimasa Takeda | Chief Accounting Officer & Corp. Controller |
| Mr. Iwaaki Taniguchi | Sr. VP of Corp. Fin. & Controlling Department |
| Mr. Gabriele Ricci | Chief Data & Technology Officer |
| Mr. Christopher David O'Reilly | Global Head of Investor Relations & Global Fin. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 9.6246 |
|---|---|
| Trailing PE: | 29.6332 |
| Price-to-Book MRQ: | 0.9712 |
| Price-to-Sales TTM: | 0.0127 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 47347 |